{"id":"group-b-levofloxacin-triple-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal discomfort"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tendinopathy"},{"rate":null,"effect":"QT prolongation"}]},"_chembl":{"chemblId":"CHEMBL33","moleculeType":"Small molecule","molecularWeight":"361.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and repair. The triple therapy formulation combines levofloxacin with additional antimicrobial agents (typically clarithromycin and amoxicillin or similar) to provide synergistic activity against resistant pathogens, particularly for eradication of Helicobacter pylori and other resistant infections.","oneSentence":"Levofloxacin triple therapy combines a fluoroquinolone antibiotic with two additional agents to inhibit bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:47:18.917Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori eradication in peptic ulcer disease"},{"name":"Resistant bacterial infections"}]},"trialDetails":[{"nctId":"NCT05332444","phase":"PHASE4","title":"Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-11","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT06088316","phase":"PHASE4","title":"Efficacy of Amoxicillin-Esomeprazole HDDT Compared to Levofloxacin Triple Therapy for H. Pylori Eradication: A RCT","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-02-10","conditions":"Helicobacter Pylori Infection, Helicobacter Pylori Eradication","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"group-B : Levofloxacin triple therapy","genericName":"group-B : Levofloxacin triple therapy","companyName":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","companyId":"bangabandhu-sheikh-mujib-medical-university-dhaka-bangladesh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levofloxacin triple therapy combines a fluoroquinolone antibiotic with two additional agents to inhibit bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms. Used for Helicobacter pylori eradication in peptic ulcer disease, Resistant bacterial infections.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}